Clinical Trials Logo

Leukemia, Myelogenous, Acute clinical trials

View clinical trials related to Leukemia, Myelogenous, Acute.

Filter by:
  • None
  • Page 1

NCT ID: NCT01999556 Completed - Clinical trials for Leukemia, Myelogenous, Acute

LCI-HEM-SPEC-001: Tissue Collection for Genetic Analysis of Acute Myelogenous Leukemia

Start date: November 2013
Phase:
Study type: Observational

The purpose of this study is to obtain high quality specimens for molecular studies for the identification and characterization of genetic mutations involved in the pathogenesis of familial myeloid malignancies. Specimens obtained will be de-identified, linked to basic clinical data, and sent to Washington University (Division of Oncology, St. Louis, MO) for molecular analyses. Some specimens sent to Washington University may also be used for quality control analyses.

NCT ID: NCT01158885 Terminated - Clinical trials for Minimal Residual Disease

Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia

Start date: August 2010
Phase: Phase 2
Study type: Interventional

This study will test the ability of clofarabine + cytarabine to eliminate minimal residual disease (MRD) in acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) patients whose bone marrows exhibit complete remission by morphology. The toxicity profile of this regimen will be evaluated in addition to toxicity experienced by patients who proceed to stem cell transplant. Overall length of remission will also be collected.

NCT ID: NCT01106950 Terminated - Clinical trials for Leukemia, Myelogenous, Acute

Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)

Start date: July 2010
Phase: Phase 2
Study type: Interventional

This is a phase II therapeutic study of related donor HLA-haploidentical NK-cell based therapy after a high dose of fludarabine/cyclophosphamide with denileukin diftitox preparative regimen for the treatment of poor prognosis acute myelogenous leukemia (AML).

NCT ID: NCT01085656 Terminated - Clinical trials for Myelodysplastic Syndromes

A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS

Start date: February 2011
Phase: Phase 1
Study type: Interventional

This study is intended to determine the safety and maximum tolerated dose of a drug, OXi4503 (combretastatin A1 diphosphate, CA1P, OXiGENE), in patients with relapsed and refractory AML and MDS.

NCT ID: NCT00619879 Recruiting - Clinical trials for Leukemia, Lymphoblastic, Acute

Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies

Start date: March 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to show that myeloablative hematopoietic progenitor cell transplantation (HPCT) continues to offer acceptable disease-free survival for select patients requiring HPCT.